Saturday, August 01, 2015 10:39:41 PM
I think Gerald is very eager which is good but also presents challenges. His eagerness has really done a good job diversifying the company. He is now going to have to be precise and execute. I am not too concerned with the dilution because I feel we have gained a lot of value from the money and shares spent. ESS cost a lot of our cash and shares but in my opinion was a steal. Also to note that the company most likely won't be diluting us to buy anymore products any time soon and further dilution (yes we will be diluted further) will provide necessary capital to uplist and move the products forward.
I also would like to hear more from their solid board but when I see us getting publications and getting orphan status and see data then I know they are working hard. That stuff is not easy and is essential to create value and the eye of both doctors and big pharma.
Gerald's performance has been nothing short of spectacular. He has done more since founding the company then anyone would of ever thought. I personally think that NASDAQ oriented institutions are thinking that they wished he worked for them. Remember that these institutions know how to play the game and are the best in the industry at buying cheap shares.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM